Sny, Gsk, & Otc:pwrm: Weekly Pharma Roundup: Gsk Settles, Vivus Disappoints, Ely Lilly Axes

SNY, Sanofi-Aventis

Recent News: Weekly Pharma Roundup: GSK Settles, Vivus Disappoints, Ely Lilly Axes

SNY, a pharmaceutical company, contributes to enhancing life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in the United States and Europe.

SNY and the Juvenile Diabetes Research Foundation (JDRF) reported a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease both those living with the disease and the newly diagnosed as well as preventing diabetes in those at risk.

Toward those goals, the partnership will focus on therapeutics such as immune therapies and beta cell regeneration.

Under the partnership, sanofi-aventis and JDRF will jointly provide academic investigators and non-profit medical research organizations with funding to conduct research projects in regeneration and immune therapy. This partnership will provide sanofi-aventis with options to the intellectual property developed by researchers who receive funding through the program.

More about SNY at en.sanofi-aventis.com

_________________________________


GSK, GlaxoSmithKline plc

GSK, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company offers prescription medicines to treat a range of conditions, such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer.

GSK and and Genmab A/S reported that the European Commission (EC) has granted a conditional marketing authorization for Arzerra(TM) (ofatumumab) for the treatment of refractory chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow. Ofatumumab is indicated for the treatment of CLL in patients who are refractory (have not responded) to fludarabine and alemtuzumab. Fludarabine and alemtuzumab are standard therapies currently used to treat CLL.

Arzerra is a monoclonal antibody, a type of biotechnology product. Antibodies that occur in nature are produced by the immune system in response to invaders. Arzerra binds to a specific protein found on the surface of both normal and malignant B cells, making the cells more susceptible to immune system attack.

Arzerra is manufactured by GSK.

More about GSK at www.gsk.com



_________________________________



POWER 3 MEDICAL PRODUCTS (OTC BB: PWRM.OB)

PWRM is now available for $0.037 cents a share with an RSI creeping closer to 30 which could be interpreted as a time to buy. Since the beginning of June 2010 PWRM has been trading in a channel. Pay attention for a possible breakout. PWRM deserves to be watched very closely! A breakout could be an indicator of possible momentum.

PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:

Processes - The manner in which the discoveries are made and tests developed
Discoveries - Protein disease footprints,
Products - Early detection tests, Biomarkers, and Drug Targets

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance:

The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below:

Two of Power3 Medical Areas of Research

Breast Cancer

Power3s early indication breast cancer NAF protein footprint test
More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer
NAF footprints for individualized therapy



Neurodegenerative Diseases - ALS (Lou Gehrigs Disease), Alzheimers Disease, Parkinsons Disease, Other Neurological Disorders

Power3s blood serum test for distinguishing between the neurodegenerative diseases
Blood serum biomarkers and drug targets for neurodegenerative disease



Resistance to Chemotherapy

Power3s test for prediction of response to drug therapy in cancer
Biomarkers and drug targets for treatment and monitoring of drug resistance





Continue your research at www.power3medical.com

*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************




THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEpicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

*******************************************